Medpace Holdings Inc (MEDP)

Investment Committee Summary

Investment Thesis

Medpace provides clinical research-based drug and medical device development services across North America, Europe and Asia. As a contract research organisation its revenue is a backlog business: awards are booked, then converted into revenue over the life of a study, so reported growth lags the true order rate by several quarters in both directions and the headline revenue line is a poor early indicator. An operating margin near 21% on a services model, with net cash of ~$0.5B, is strong for the category and reflects an owned-infrastructure, full-service approach rather than a staffing pass-through. At $591 on 9 September 2026 the shares carry roughly 36 times forward earnings and are trading rich to the triangulated fair value (-17%), with the probability-weighted expected value at $529. The decisive variable is net new business awards, and behind them the funding environment of biopharma sponsors — their ability to raise and commit research capital sets the industry's order book long before it sets anyone's revenue. The most damaging risk is cancellation: backlog is not contracted revenue, and a funding squeeze converts book into cancellations rather than into billings.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($591) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

Backlog is both the mechanism and the illusion. A research organisation's book is cancellable, so when sponsor funding tightens the order book does not merely stop growing — it shrinks as studies are paused or killed, and revenue that looked contracted leaves with them. Because the model carries its own infrastructure and clinical staff, the 21% margin de-gears hard on falling utilisation: people cannot be released as fast as studies are cancelled without destroying the capability that wins the next award. Add geographic and regulatory restriction on where studies may be run — which reshapes the served market administratively rather than cyclically — and the earnings base steps down instead of passing through a trough. The multiple does the rest, since a name held near 36 times earnings on a record of consistent awards de-rates sharply the first time awards disappoint. The structural leg carries a target below the 52-week low, and the engine flags its modelled probability of clearing today's price as beneath the plausible band.

Key Debate

P/E Multiple explains 62% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

What the Market Is Pricing In

At the current price, the market pays 33.4× consensus forward EPS, vs the house DCF terminal 27.0×, and a peer median 34.4×. The house DCF sits 19% below spot, so the market is pricing in more than the house case — roughly 2.6pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily FCF-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Biopharma-Funding / China / Bioprocessing Reset' downside ($233) to a 'Bull — Re-Rate' bull case ($935); the probability-weighted blend (PWEV $529) is -11% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 1.3% of revenue; free cash flow net of SBC is $0.65B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Biopharma-Funding / China / Bioprocessing Reset (20%, $233). Structural impairment — biopharma-funding / China / demand reset: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• R&D-Spend Recession (17%, $395). Cyclical downturn — biopharma R&D & commercial budgets + consumable/service pull-through weakens for 1–2 years before normalising.
• Base — Tools + Services Growth (35%, $549). Mid-cycle — normalised biopharma R&D & commercial budgets + consumable/service pull-through; disciplined capital allocation; steady returns.
• Growth — Bioprocessing / Biologics Recovery (20%, $741). Upside — biopharma spend recovery + mix lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Re-Rate (8%, $935). Upside tail — sustained tight conditions or a structural re-rate on biopharma spend recovery + mix.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $474 and 30% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (62% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 27.0x terminal FCF multiple → $476. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $305; the peer-median forward P/E is 34.4x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 47% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Life-Science Tools, Services & Software multiple (AI re-rating) (base 32.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 32.7× (simple median 34.4×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $373–$629, centre $484 (-18% vs spot); spot sits at the 85th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Re-Rate): $935.

Company Overview & Business Model

Medpace Holdings Inc — HEALTHCARE · DIAGNOSTICS & RESEARCH. Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.

How it makes money.

Edge. Wide moat — inferred from a 21% operating margin and the Life-Science tools & services business model. Durable pricing power supports a terminal multiple above the market.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Care — Devices Tools

This name sits in the Health Care — Devices Tools cluster as a Life-Science tools, services & software name. biopharma R&D spend + bioprocessing/biologics demand + CRO/clinical funding. Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: ILMN (Life-Science tools, services & software) · MEDP (Life-Science tools, services & software) · PEN (medical devices & equipment) · GMED (medical devices & equipment) · BRKR (medical devices & equipment) · BIO (Life-Science tools, services & software) · AVTR (Life-Science tools, services & software) · LNTH (medical devices & equipment) · LIVN (medical devices & equipment) · NVST (medical devices & equipment) · DOCS (Life-Science tools, services & software) · HAE (medical devices & equipment) · XRAY (medical devices & equipment)

Mapping note: name-level 'Structural — Biopharma-Funding / China / Bioprocessing Reset' (20%) + 'R&D-Spend Recession' (17%) map to cluster Reimbursement / Funding / Utilization Reset (37%); name-level 'Growth — Bioprocessing / Biologics Recovery' (20%) + 'Bull — Re-Rate' (8%) map to cluster Upside — Innovation / Recovery Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Reimbursement / Funding / Utilization Reset — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The Health Care — Devices Tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex. Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 158% — cash-backed.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.08 vs analyst floor +0.00 → delta +0.08 (n=43 mgmt / 36 Q&A; 1st pctile across the S&P book, z -2.1).

Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).

News (last 365d, 557 articles): avg ticker sentiment -0.21 (bullish 9% / bearish 46%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-10-28 (~50d) — Quarterly earnings — est. EPS $4.45 (AV EARNINGS_CALENDAR)

Forecast Track Record

• EPS surprise: beat 100% of the last 8 quarters; average surprise +9.7%.
• Prior-forecast backtest (19 snapshots, 2026-07-21→2026-09-03): directional hit-rate 53%; mean predicted -10.5% vs realised +0.0%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

5 catalysts in the next 90 days (of 13 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic revenue growth / order backlog < flat-to-negative for two consecutive quarters (2 consecutive prints). Sustained demand rollover breaks the base case toward the recession scenario.
• FY revenue ($B) < 2.75 (next reported fiscal year). (rationale withheld pending re-authoring — frozen figure or verdict)
• Probability-weighted fair value (PWEV) at the next re-run < 590.89 (any scheduled re-run). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $591; 52-week range $373–$629; engine rating SELL; house target $529 (-11%). (source: Alpha Vantage 2026-09-08, 9 September 2026)
• INFERENCE: Triangulated FV $493 (-17% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

71.4/100 (confidence band 61.4–81.5), 94th percentile of 893 covered names (as of 2026-09-08). Weighted composite under config ros-1.20.0 — every component and its inputs below.

Score history: 71.1 → 71.1 → 71.1 → 71.4 → 71.5 → 71.5 → 71.7 → 71.3.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $528.64.

Factor Exposures

Cross-sectional percentiles over 893 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.29, vs QQQ +0.25 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Put Debit Spread. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• bearish with cheap options — buy defined-risk downside
• Direction bearish from the overlay conviction/rating (read-only input).
• IV/RV at the 16th percentile of the cross-section → low vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 50th percentile of its own month-end history (decile 6). The two measures disagree here — vol is high for this name by its own history while its options are not unusually rich against its realised vol. Where they diverge, the cross-sectional measure is the one acting.
• IV term structure is in contango (longer-dated richer, slope +12.6pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.
• No live-chain Put Debit Spread was priced for this name — shown as the indicated strategy; size against a freshly pulled chain.

IV term structure (contango, slope +12.6pp): 38-DTE 35% · 101-DTE 45% · 346-DTE 47%

No live-chain Put Debit Spread was priced for this name — shown as the indicated approach; size against a fresh chain.

Alternatives: Protective Put. IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

research rating is SELL-tier — the model carries no long position.

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the SELL equity view. Chain as of 2026-09-08 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 34.7% (subdued regime) · expected move ±8.8% (2026-10-16) · put/call OI 2.87 · ATM Δ 0.54 / Θ -0.36 / ν 0.76 · next earnings 2026-10-28. Direction: NEUTRAL (implied return -16.5% to triangulated fair value $493.1).

Covered Call (if held) (Income / neutral) — Short 630 C · 2026-10-16 · premium $11.65 · yield 2.0% · priced from the listed chain (EOD marks)

Converts a near-fair holding into income by agreeing to sell at a higher strike — worth weighing when upside looks limited near fair value and being called away is acceptable. Illustrative — no outcome is implied or guaranteed.

Put Spread (income) (Income / would-own) — Short 540 P / Long 500 P · 2026-10-16 · net $6.34 · net entry $533.66 · yield 1.2% · RoR 19.0% · max loss $33.66 · priced from the listed chain (EOD marks)

Gets paid to wait for a lower entry, with the tail capped: the sold put collects premium while the cheaper long wing below it caps the maximum loss at the spread width — a defined-risk alternative to a naked cash-secured put.

Protective Collar (if held) (Hedge) — Long 530 P / Short 650 C · 2027-03-19 · net $15.35 · floor -10.0% · cap +10.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -11% vs spot
• Monte Carlo median implies -20% vs spot
• DCF fair value implies -19% vs spot — but this is terminal-value sensitive (exit-multiple $476 vs Gordon $336, 29% apart), so it carries less weight
• Bear case (Structural — Biopharma-Funding / China / Bioprocessing Reset) downside is -61% vs spot
• Net: the valuation anchor itself sits 16.5% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating warrants a Sell.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $2B + PV(terminal) $11B = EV $13B; + net cash $0.5B → equity $14B ÷ diluted shares $0.03B = $476/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $336/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 17% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $305 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (127.0); Terminal × ±15% (115.0); Revenue CAGR ±3pp (108.0); WACC ±1pp (39.0); Capex intensity ±15% (38.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 27×, FY+5 revenue $3B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.